Russell Investments Group Ltd. Has $3.94 Million Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Russell Investments Group Ltd. trimmed its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 51.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,667 shares of the company's stock after selling 66,854 shares during the period. Russell Investments Group Ltd. owned approximately 0.13% of Amphastar Pharmaceuticals worth $3,938,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in AMPH. Exchange Traded Concepts LLC boosted its holdings in Amphastar Pharmaceuticals by 0.8% during the fourth quarter. Exchange Traded Concepts LLC now owns 21,440 shares of the company's stock worth $1,326,000 after buying an additional 169 shares in the last quarter. Los Angeles Capital Management LLC boosted its stake in shares of Amphastar Pharmaceuticals by 1.3% during the 3rd quarter. Los Angeles Capital Management LLC now owns 27,443 shares of the company's stock worth $1,262,000 after acquiring an additional 358 shares in the last quarter. McGlone Suttner Wealth Management Inc. acquired a new stake in shares of Amphastar Pharmaceuticals in the 4th quarter worth approximately $28,000. Teacher Retirement System of Texas increased its stake in Amphastar Pharmaceuticals by 4.8% in the 3rd quarter. Teacher Retirement System of Texas now owns 10,967 shares of the company's stock valued at $504,000 after purchasing an additional 507 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Amphastar Pharmaceuticals by 99.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,261 shares of the company's stock worth $58,000 after buying an additional 628 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Trading Down 0.5 %

NASDAQ AMPH traded down $0.22 during mid-day trading on Friday, reaching $42.21. 595,849 shares of the stock were exchanged, compared to its average volume of 336,097. The stock has a market capitalization of $2.03 billion, a PE ratio of 14.61, a PEG ratio of 1.01 and a beta of 0.85. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.70 and a current ratio of 2.18. Amphastar Pharmaceuticals, Inc. has a 1-year low of $38.43 and a 1-year high of $67.66. The business's fifty day simple moving average is $42.57 and its 200 day simple moving average is $50.69.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $0.81 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.84 by ($0.03). The business had revenue of $178.11 million for the quarter, compared to analyst estimates of $174.90 million. Amphastar Pharmaceuticals had a return on equity of 29.17% and a net margin of 22.88%. On average, research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday. StockNews.com cut Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, February 29th. Finally, JPMorgan Chase & Co. began coverage on Amphastar Pharmaceuticals in a report on Tuesday, March 5th. They issued an "overweight" rating and a $60.00 price target for the company. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $66.00.

Insiders Place Their Bets

In other news, Director Michael A. Zasloff sold 12,500 shares of the company's stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total transaction of $589,750.00. Following the completion of the transaction, the director now owns 21,326 shares of the company's stock, valued at approximately $1,006,160.68. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last ninety days, insiders have sold 14,000 shares of company stock valued at $655,145. Insiders own 27.10% of the company's stock.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.